Condition:   Surgical Wound Dehiscence
Interventions:   Device: Strattice(TM) Reconstructive Tissue Matrix;   Procedure: Suture/suture with absorbable mesh
Sponsor:   LifeCell
Not yet recruiting - verified March 2010

Condition:   Hypertension
Interventions:   Drug: Azilsartan medoxomil (TAK-491);   Drug: Azilsartan medoxomil (TAK-491);   Drug: Azilsartan medoxomil (TAK-491);   Drug: Azilsartan medoxomil (TAK-491)
Sponsor:   Takeda Global Research & Development Center, Inc.
Not yet recruiting - verified February 2010

Condition:   Severe Aortic Valve Stenosis
Intervention:   Device: Medtronic CoreValve System
Sponsor:   Medtronic Bakken Research Center
Recruiting - verified March 2010

Condition:   HIV Infections
Interventions:   Biological: HIV-v (Low Dose);   Biological: HIV-v (High Dose);   Biological: HIV-v (Control)
Sponsor:   PepTcell Limited
Recruiting - verified February 2010

Condition:   Asthma
Interventions:   Drug: CHF 5188 pMDI;   Drug: Budesonide extrafine pMDI;   Drug: Seretide(r) Evohaler(r)
Sponsor:   Chiesi Farmaceutici S.p.A.
Recruiting - verified February 2010

Condition:   Multiple Myeloma
Intervention:   Drug: KW-2478 and bortezomib
Sponsors:   Kyowa Hakko Kirin Pharma, Inc.;   Kyowa Hakko Kirin UK, Ltd.;   Kyowa Hakko Kirin Company, Limited
Not yet recruiting - verified January 2010

Condition:   Psoriasis
Interventions:   Drug: Ustekinumab/Methotrexate;   Drug: Ustekinumab/Methotrexate
Sponsor:   Janssen-Cilag International NV
Recruiting - verified February 2010

Condition:   Sanfilippo Syndrome Type A
Intervention:   Other: assessment
Sponsor:   Shire Human Genetic Therapies, Inc.
Recruiting - verified March 2010

Condition:   Hepatitis C Virus
Interventions:   Drug: BMS-650032;   Drug: BMS-650032;   Drug: BMS-650032;   Drug: BMS-650032;   Drug: Peginterferon Alfa-2a;   Drug: Peginterferon Alfa-2a;   Drug: Ribavirin;   Drug: Ribavirin
Sponsor:   Bristol-Myers Squibb
Recruiting - verified December 2009

Conditions:   Diabetes Mellitus, Type 2;   Cardiovascular Diseases;   Risk Factors
Interventions:   Drug: Canagliflozin on background standard of care for diabetes;   Drug: Placebo on background standard of care for diabetes
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   George Institute, Sydney, Australia
Recruiting - verified February 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: taspoglutide;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Recruiting - verified March 2010

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: FF/GW642444 Inhalation Powder;   Drug: GW642444 Inhalation Powder
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Macular Degeneration
Interventions:   Device: Epimacular Brachytherapy;   Drug: Ranibizumab
Sponsors:   King's College Hospital NHS Trust;   NeoVista
Recruiting - verified February 2010

Condition:   Malignant Melanoma
Interventions:   Drug: RO5185426;   Drug: dacarbazine
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Melanoma
Interventions:   Drug: Tasisulam;   Drug: Paclitaxel
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: Aclidinium bromide;   Drug: Placebo
Sponsors:   Almirall, S.A.;   Forest Laboratories
Recruiting - verified March 2010

Condition:   Asthma
Intervention:   Biological: Mepolizumab (treatment) - Severe asthma
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide once weekly;   Drug: insulin detemir
Sponsors:   Amylin Pharmaceuticals, Inc.;   Eli Lilly and Company
Recruiting - verified December 2009

Condition:   Acromegaly
Intervention:   Drug: BIM 23A760
Sponsor:   Ipsen
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Drug: CS-7017;   Drug: Placebo
Sponsor:   Daiichi Sankyo Inc.
Recruiting - verified March 2010

Condition:   Thyroid Neoplasm
Interventions:   Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
Sponsors:   Bayer;   Onyx Pharmaceuticals
Recruiting - verified March 2010

Condition:   Haemophilia A
Interventions:   Drug: recombinant factor VIII (N8);   Drug: recombinant factor VIII (N8)
Sponsor:   Novo Nordisk
Recruiting - verified March 2010

Conditions:   Cancer;   Advanced Solid Malignancies
Intervention:   Drug: AZD4547
Sponsor:   AstraZeneca
Recruiting - verified March 2010

Condition:   Glioblastoma
Interventions:   Procedure: Radiotherapy;   Procedure: Radiotherapy;   Drug: BIBW2992;   Drug: BIBW2992;   Drug: Temozolomide
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (HOE901);   Drug: Insulin aspart;   Drug: Insulin Glulisine
Sponsor:   Sanofi-Aventis
Recruiting - verified March 2010

Conditions:   Human Papillomavirus (HPV) Type 16/18 Infections;   Cervical Neoplasia
Intervention:   Procedure: Gynaecological follow-up
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Hyperparathyroidism, Primary
Intervention:  
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Endometrial Cancer
Interventions:   Drug: BN83495;   Drug: Megestrol Acetate (MA)
Sponsor:   Ipsen
Recruiting - verified February 2010

Condition:   Immune Thrombocytopenic Purpura
Interventions:   Drug: eltrombopag;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Asthma
Interventions:   Drug: PF-03526299;   Drug: Placebo;   Drug: Fluticasone propionate
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Lymphoma, B-Cell;   Lymphoma, Diffuse
Interventions:   Drug: inotuzumab ozogamicin (CMC-544);   Drug: rituximab
Sponsor:   Wyeth
Recruiting - verified March 2010

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified March 2010

Conditions:   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention:   Drug: SGN-35
Sponsor:   Seattle Genetics, Inc.
Recruiting - verified February 2010

Condition:   Prostate Cancer
Interventions:   Drug: Ipilimumab;   Drug: Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2010

Condition:   Hepato Cellular Carcinoma (HCC)
Interventions:   Drug: Brivanib;   Drug: Placebo;   Drug: Sorafenib;   Drug: Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified November 2009

Conditions:   Non-small Cell Lung Cancer;   Anemia;   Cancer;   Lung Cancer
Interventions:   Drug: darbepoetin alfa 500 mcg Q3W;   Drug: placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Non-small Cell Lung Cancer (NSCLC)
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: CT-322;   Drug: Bevacizumab;   Drug: Bevacizumab placebo (ie saline solution)
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2009

Conditions:   Colorectal Neoplasms;   Neoplasm Metastasis
Interventions:   Drug: aflibercept (AVE0005);   Drug: oxaliplatin;   Drug: 5-FU;   Drug: Folinic Acid
Sponsor:   Sanofi-Aventis
Recruiting - verified March 2010

Condition:   Systemic Sclerosis
Intervention:   Drug: treprostinil diethanolamine
Sponsor:   United Therapeutics
Not yet recruiting - verified February 2009

Condition:   Haemophilia A
Interventions:   Drug: recombinant factor VIII (N8);   Procedure: Blood drawn for laboratory testing
Sponsor:   Novo Nordisk
Recruiting - verified March 2010

Conditions:   Metastatic;   Colorectal Cancer
Interventions:   Drug: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin);   Drug: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Sponsors:   Bayer;   Onyx Pharmaceuticals
Recruiting - verified February 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Apixaban;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke University
Recruiting - verified October 2009

Condition:   Non-Hodgkin's Lymphoma
Interventions:   Drug: RO5072759;   Drug: RO5072759;   Drug: CHOP(cyclophosphamide,doxorubicin,vincristine,prednisone);   Drug: FC(fludarabine,cyclophosphamide)
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: OFC Infusion;   Drug: FC infusion
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   HIV-1
Interventions:   Other: Standard of care tests if needed;   Other: Standard of care tests if needed;   Other: Standard of care tests if needed;   Other: Standard of care tests if needed;   Other: Standard of care tests if needed;   Other: Standard of care tests if needed
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   HIV-1
Interventions:   Drug: UK-453,061 Dose 1;   Drug: UK-453,061 Dose 2;   Drug: Etravirine
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   HIV-1
Interventions:   Drug: UK-453, 061;   Drug: UK-453, 061;   Drug: EFV +TVA
Sponsor:   Pfizer
Recruiting - verified February 2010

Conditions:   Acute Coronary Syndrome;   Myocardial Infarction;   Myocardial Ischemia;   Unstable Angina
Intervention:   Drug: Rivaroxaban; Placebo
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Bayer
Recruiting - verified February 2010

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: BIBF 1120 plus docetaxel;   Drug: placebo plus docetaxel
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Conditions:   Soft Tissue Sarcomas;   Translocation-Related Sarcomas (TRS)
Intervention:   Drug: Trabectedin, ET 743 and Yondelis
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   PharmaMar
Recruiting - verified February 2010

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Placebo;   Drug: Pemetrexed;   Other: Best Supportive Care
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Ulcerative Colitis
Interventions:   Drug: CP- 690 550;   Drug: CP- 690 550;   Drug: CP- 690 550;   Drug: CP- 690 550;   Other: placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Gastrointestinal Stromal Tumor (GIST)
Interventions:   Drug: Nilotinib (AMN107);   Drug: imatinib (STI571)
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified February 2010

Condition:   ADHD
Interventions:   Drug: SPD489 (lisdexamfetamine dimesylate);   Drug: Placebo
Sponsor:   Shire Pharmaceutical Development
Recruiting - verified March 2010

Conditions:   Lung Cancer;   Small Cell Lung Cancer;   Solid Tumors;   Extensive-Stage Small Cell Lung Cancer
Interventions:   Drug: AMG 102 in combination with Cisplatin/Etopiside;   Drug: AMG 479 in combination with Carboplatin/Etopiside;   Drug: AMG 102 in combination with Carboplatin/Etopiside;   Drug: AMG 479 in combination with Cisplatin/Etopiside
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-FU;   Drug: 5-FU;   Drug: Leucovorin;   Drug: 5-FU;   Drug: Irinotecan
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Conditions:   Systemic Sclerosis;   Scleroderma
Interventions:   Drug: treprostinil diethanolamine;   Drug: placebo
Sponsor:   United Therapeutics
Recruiting - verified February 2010

Condition:   Crohn's Disease
Intervention:   Drug: Ustekinumab; CNTO1275
Sponsor:   Centocor, Inc.
Recruiting - verified March 2010

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Erlotinib;   Drug: PF-00299804
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Diabetic Foot Ulcer
Intervention:   Drug: Fragmin
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   ADHD
Interventions:   Drug: LDX;   Drug: Methylphenidate Hydrochloride;   Drug: Placebo
Sponsor:   Shire Pharmaceutical Development
Recruiting - verified February 2010

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: RG1507;   Drug: Placebo;   Drug: RG1507;   Drug: Placebo;   Drug: erlotinib [Tarceva]
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Optic Neuropathy, Ischemic
Intervention:  
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified October 2009

Condition:   Soft Tissue Sarcoma
Intervention:   Drug: PAZOPANIB
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Acromegaly
Intervention:  
Sponsor:   Ipsen
Recruiting - verified February 2010

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: ofatumumab (GSK1841157) infusion;   Drug: chlorambucil, tablets
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Alzheimer's Disease
Interventions:   Biological: PF-04360365 0.1 mg/kg;   Biological: PF-04360365 0.5 mg/kg;   Biological: PF-04360365 1 mg/kg;   Drug: Placebo;   Biological: PF-04360365 3 mg/kg;   Biological: PF-04360365 8.5 mg/kg
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions:   Drug: Sunitinib;   Drug: Pazopanib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Conditions:   Esophagogastric Junction Adenocarcinoma;   Gastric Cancer;   Esophageal Cancer
Interventions:   Drug: Capecitabine;   Drug: Epirubicin;   Drug: AMG 102;   Drug: Cisplatin
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Foot Ulcer, Diabetic
Interventions:   Other: Medical Food;   Other: Drink mix calorically similar to experimental product
Sponsor:   Abbott Nutrition
Recruiting - verified March 2010

Condition:   Thyroid Cancer
Interventions:   Drug: XL184;   Drug: Placebo
Sponsor:   Exelixis
Recruiting - verified March 2010

Condition:   Cervical Degenerative Disc Disease
Intervention:   Device: Arthroplasty (DISCOVER™)
Sponsor:   DePuy International
Recruiting - verified February 2010

Conditions:   Hormone Refractory Prostate Cancer;   Bone Metastases
Interventions:   Drug: Alpharadin (Radium-223);   Drug: Placebo
Sponsor:   Algeta ASA
Recruiting - verified March 2009

Condition:   Carcinoma, Hepatocellular
Interventions:   Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified March 2010

Condition:   Alzheimer Disease
Interventions:   Drug: bapineuzumab;   Drug: placebo
Sponsor:   Wyeth
Recruiting - verified February 2010

Conditions:   Prevention of Venous Thromboembolism;   Cancer
Interventions:   Drug: AVE5026;   Drug: Placebo
Sponsor:   Sanofi-Aventis
Recruiting - verified March 2010

Condition:   Alzheimer Disease
Interventions:   Drug: bapineuzumab;   Drug: placebo
Sponsor:   Wyeth
Recruiting - verified February 2010

Condition:   Human Immunodeficiency Virus
Interventions:   Drug: Maraviroc along with an optimized background antiretroviral drug regimen;   Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Diabetic Foot Ulcer
Interventions:   Drug: Fragmin/ Dalteparin Sodium;   Drug: Placebo for Fragmin/ Dalteparin Sodium
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: Placebo;   Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor:   Hoffmann-La Roche
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Drug: bevacizumab [Avastin];   Drug: Standard chemotherapy
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Venous Thrombosis
Interventions:   Drug: Apixaban;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer
Recruiting - verified February 2010

Conditions:   MDS;   Myelodysplastic Syndromes;   Thrombocytopenia
Interventions:   Drug: Placebo;   Biological: Romiplostim
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: ZD4054;   Drug: Luteinising hormone-releasing hormone analogue (LHRHa);   Drug: Megace;   Drug: Estradiol;   Drug: Prednisolone;   Drug: Ketoconazole;   Drug: Docetaxel
Sponsor:   AstraZeneca
Recruiting - verified February 2010

Condition:   Prostate Cancer
Interventions:   Drug: Docetaxel;   Drug: ZD4054
Sponsor:   AstraZeneca
Recruiting - verified February 2010

Conditions:   Colorectal Neoplasms;   Neoplasm Metastasis
Interventions:   Drug: Aflibercept (AVE0005);   Drug: Placebo
Sponsors:   Sanofi-Aventis;   Regeneron Pharmaceuticals;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010

Condition:   Non-Small-Cell Lung Cancer
Interventions:   Drug: Drug: pemetrexed;   Drug: Drug: erlotinib
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: erlotinib [Tarceva];   Drug: Avastin;   Drug: Standard platinum-based chemotherapy
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Aspergillosis
Interventions:   Drug: voriconazole;   Drug: anidulafungin;   Drug: voriconazole
Sponsors:   Pfizer;   Mycoses Study Group
Recruiting - verified February 2010

Condition:   Epilepsy
Interventions:   Drug: lacosamide;   Drug: lacosamide
Sponsor:   UCB, Inc.
Recruiting - verified March 2010

Condition:   Moderate Risk of CVD
Interventions:   Drug: Aspirin (Acetylsalicylic acid, BAYE4465);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Biological: Trastuzumab;   Drug: Lapatinib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Tumor Antigen-positive Non-Small Cell Lung Cancer
Interventions:   Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic;   Biological: Placebo Control
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Temsirolimus;   Drug: Sorafenib
Sponsor:   Wyeth
Recruiting - verified February 2010

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: AMG 706;   Drug: placebo
Sponsors:   Amgen;   Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010

Condition:   Neoplasms
Intervention:   Drug: SU011248
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   HIV Infections
Intervention:   Drug: maraviroc
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Cancer (Solid Tumors)
Intervention:   Drug: BMS-690514
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2010

Conditions:   Glioma;   Medulloblastoma
Interventions:   Drug: Irinotecan;   Drug: Temozolomide
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: Herceptin;   Drug: Docetaxel
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Kidney Neoplasms
Interventions:   Drug: Sunitinib malate;   Other: Placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Interventions:   Drug: capecitabine;   Other: clinical observation;   Procedure: adjuvant therapy
Sponsor:   Southampton University Hospitals NHS Trust
Recruiting - verified March 2008

Conditions:   Heart Failure;   Anemia;   Cardiovascular Disease;   Ventricular Dysfunction;   Congestive Heart Failure
Interventions:   Drug: Darbepoetin alfa;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Idiopathic Thrombocytopenic Purpura
Intervention:   Drug: eltrombopag olamine (SB-497115-GR)
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Conditions:   Ovarian Cancer;   Merkel Cell Carcinoma;   SCLC
Intervention:   Drug: BB-10901
Sponsor:   ImmunoGen, Inc.
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Other: pharmacological study;   Radiation: radiation therapy
Sponsor:   German High-Grade Non-Hodgkin's Lymphoma Study Group
Recruiting - verified July 2009

Condition:   Secondary Hyperparathyroidism
Intervention:   Drug: Sensipar (Cinacalcet HCl)
Sponsor:   Amgen
Recruiting - verified February 2010

Condition:   Heart Failure
Interventions:   Drug: Eplerenone;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsor:   European Organization for Research and Treatment of Cancer
Recruiting - verified July 2009